Patents by Inventor Andrew Quoc Viet

Andrew Quoc Viet has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PYRROLIDINONE DERIVATIVES AS FORMYL PEPTIDE 2 RECEPTOR AGONISTS
    Publication number: 20220002281
    Abstract: The disclosure relates to compounds of formula (I), which are formyl peptide 2 (FPR2) receptor agonists and/or formyl peptide 1 (FPR1) receptor agonists. The disclosure also provides compositions and methods of using the compounds, for example, for the treatment of atherosclerosis, heart failure, and related diseases.
    Type: Application
    Filed: November 25, 2019
    Publication date: January 6, 2022
    Inventors: Nicholas R. WURTZ, James A. JOHNSON, Zulan PI, Andrew Quoc VIET
  • Piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists
    Patent number: 11186544
    Abstract: The disclosure relates to compounds of formula (I), which are formyl peptide 2 (FPR2) receptor agonists and/or formyl peptide 1 (FPR1) receptor agonists. The disclosure also provides compositions and methods of using the compounds, for example, for the treatment of atherosclerosis, heart failure, chronic obstructive pulmonary disease (COPD), and related diseases.
    Type: Grant
    Filed: June 8, 2018
    Date of Patent: November 30, 2021
    Assignee: Bristol-Myers Squibb Company
    Inventors: Nicholas R. Wurtz, Pravin Sudhakar Shirude, Andrew Quoc Viet
  • Thioether triazolopyridine and triazolopyrimidine inhibitors of myeloperoxidase
    Patent number: 10981879
    Abstract: The present invention provides compounds of Formula (I): wherein A, X and Y are as defined in the specification, and compositions comprising any of such novel compounds. These compounds are myeloperoxidase (MPO) inhibitors and/or eosinophil peroxidase (EPX) inhibitors, which may be used as medicaments.
    Type: Grant
    Filed: September 28, 2018
    Date of Patent: April 20, 2021
    Assignee: Bristol-Myers Squibb Company
    Inventors: Andrew Quoc Viet, Nicholas R. Wurtz
  • Triazolopyridine inhibitors of myeloperoxidase
    Patent number: 10316035
    Abstract: The present invention provides compounds of Formula (I): wherein A, Y and R1 are each as defined in the specification, and compositions comprising any of such novel compounds. These compounds are myeloperoxidase (MPO) inhibitors and/or eosinophil peroxidase (EPX) inhibitors, which may be used as medicaments.
    Type: Grant
    Filed: August 30, 2016
    Date of Patent: June 11, 2019
    Assignee: Bristol-Myers Squibb Company
    Inventors: Andrew Quoc Viet, Nicholas Ronald Wurtz, Scott A. Shaw, Ellen K. Kick, Andrew K. Dilger, Kumar Balashanmuga Pabbisetty
  • THIOETHER TRIAZOLOPYRIDINE AND TRIAZOLOPYRIMIDINE INHIBITORS OF MYELOPEROXIDASE
    Publication number: 20190031623
    Abstract: The present invention provides compounds of Formula (I): wherein A, X and Y are as defined in the specification, and compositions comprising any of such novel compounds. These compounds are myeloperoxidase (MPO) inhibitors and/or eosinophil peroxidase (EPX) inhibitors, which may be used as medicaments.
    Type: Application
    Filed: September 28, 2018
    Publication date: January 31, 2019
    Inventors: Andrew Quoc Viet, Nicholas R. Wurtz
  • TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE
    Publication number: 20180244671
    Abstract: The present invention provides compounds of Formula (I): wherein A, Y and R1 are each as defined in the specification, and compositions comprising any of such novel compounds. These compounds are myeloperoxidase (MPO) inhibitors and/or eosinophil peroxidase (EPX) inhibitors, which may be used as medicaments.
    Type: Application
    Filed: August 30, 2016
    Publication date: August 30, 2018
    Applicant: Bristol-Meyers Squibb Company
    Inventors: Andrew Quoc Viet, Nicholas Ronald Wurtz, Scott A. Shaw, Ellen K. Kick, Andrew K. Dilger, Kumar Balashanmuga Pabbisetty
  • Triazolopyridine and triazolopyrimidine inhibitors of myeloperoxidase
    Patent number: 9920075
    Abstract: The present invention provides compounds of Formula (I): wherein A and R1 are each as defined in the specification, and compositions comprising any of such novel compounds. These compounds are myeloperoxidase (MPO) inhibitors and/or eosinophil peroxidase (EPX) inhibitors, which may be used as medicaments.
    Type: Grant
    Filed: September 9, 2015
    Date of Patent: March 20, 2018
    Assignee: Bristol-Myers Squibb Company
    Inventors: Nicholas R. Wurtz, Andrew Quoc Viet, Scott A. Shaw, Benjamin P. Vokits, Ellen K. Kick, Meriah Neissel Valente, Andrew K. Dilger, Kumar Balashanmuga Pabbisetty, Sutjano Jusuf
  • TRIAZOLOPYRIDINE AND TRIAZOLOPYRIMIDINE INHIBITORS OF MYELOPEROXIDASE
    Publication number: 20170247396
    Abstract: The present invention provides compounds of Formula (I): wherein A and R1 are each as defined in the specification, and compositions comprising any of such novel compounds. These compounds are myeloperoxidase (MPO) inhibitors and/or eosinophil peroxidase (EPX) inhibitors, which may be used as medicaments.
    Type: Application
    Filed: September 9, 2015
    Publication date: August 31, 2017
    Inventors: Nicholas R. Wurtz, Andrew Quoc Viet, Scott A. Shaw, Benjamin P. Vokits, Ellen K. Kick, Meriah Neissel Valente, Andrew K. Dilger, Kumar Balashanmuga Pabbisetty, Sutjano Jusuf
  • THIOETHER TRIAZOLOPYRIDINE AND TRIAZOLOPYRIMIDINE INHIBITORS OF MYELOPEROXIDASE
    Publication number: 20170247343
    Abstract: The present invention provides compounds of Formula (I): wherein A, X and Y are as defined in the specification, and compositions comprising any of such novel compounds. These compounds are myeloperoxidase (MPO) inhibitors and/or eosinophil peroxidase (EPX) inhibitors, which may be used as medicaments.
    Type: Application
    Filed: September 9, 2015
    Publication date: August 31, 2017
    Applicant: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Andrew Quoc Viet, Nicholas R. Wurtz